资讯

行业新闻

与原料药、中间体及成品制剂伙伴相关的授权交易、监管决策与市场动态。

2026.07.03industry

PureTech Startup Celea Raises $180M to Develop Next-Generation IPF Therapy, Signaling Growing Respiratory Market

Celea, incubated by PureTech Health, secures $180M from RA Capital and Leaps by Bayer to advance an improved version of Roche's Esbriet for idiopathic pulmonary fibrosis, highlighting expanding API demand in respiratory therapeutics.

2026.07.03industry

Roche's Divarasib Outperforms Amgen and BMS KRAS Inhibitors in Head-to-Head Lung Cancer Trial

Roche's Phase 3 trial demonstrates superior progression-free survival for divarasib over Amgen's Lumakras and BMS's Krazati in KRAS G12C-mutated NSCLC, reshaping the competitive landscape and signaling increased API demand for oncology suppliers.

2026.07.02industry

Ipsen's $800M Memo Therapeutics Deal Targets BK Polyomavirus in Kidney Transplant Patients

French pharma Ipsen acquires Swiss biotech Memo Therapeutics for up to $800M, gaining potravitug — a monoclonal antibody targeting BK polyomavirus in kidney transplant recipients — with a pivotal Phase 2/3 trial planned for late 2026.

2026.07.02industry

FDA Warns Sanofi's Genzyme Irish Plant Over Data Integrity Failures, Signaling Tighter Manufacturing Scrutiny

FDA issues warning letter to Genzyme's Waterford, Ireland facility citing data integrity violations and improperly canceled deviations, raising quality concerns for Sanofi's rare disease biologics production and the broader CDMO supply chain.

2026.07.01industry

Anthropic Enters Pharmaceutical Drug Development, Launching Claude Science for Researchers

AI giant Anthropic announces its entry into drug development alongside the launch of Claude Science, a new application for researchers and the pharma industry, signaling deepening AI involvement in pharmaceutical R&D.

2026.07.01industry

Zymeworks Acquires Theravance for $929M After Clinical Setbacks, Signaling Mid-Cap Biopharma Consolidation

Royalty management company Zymeworks acquires Theravance Biopharma for $929 million following ampreloxetine clinical failure, highlighting how pipeline setbacks drive mid-cap consolidation with implications for API supply chains.

2026.06.30industry

Ipsen's $450M Kartos Acquisition Signals Continued Appetite for Blood Cancer APIs

French pharma company Ipsen acquires Kartos Therapeutics for $450M upfront, gaining an MDM2-targeting blood cancer drug candidate originally in-licensed from Amgen, highlighting sustained oncology API demand.

2026.06.30industry

Sobi's Gout Drug Rejected by FDA Over Manufacturing Concerns, Highlighting Third-Party Production Risks

FDA issues Complete Response Letter to Sobi for its gout combination therapy, citing production concerns and issues at third-party manufacturing sites — a cautionary signal for API and CDMO partners.

2026.06.29industry

At BIO 2026, Tension Over China Biotech Deal Regulation Looms Large

At the BIO International Convention in San Diego, US-China biotech deal regulation dominated discussions as policymakers intensify scrutiny of cross-border licensing agreements, with major implications for API suppliers and pharmaceutical supply chains.

2026.06.29industry

Ionis Hits 'Commercial Inflection Point' as FDA Expands Tryngolza Label

FDA approves broader label for Ionis's antisense oligonucleotide therapy Tryngolza, tripling its addressable market and validating nucleic acid therapeutics as a growing modality with significant supply chain implications.

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →